Fiduciary Financial Group LLC Purchases 253 Shares of Sanofi (NASDAQ:SNY)

Fiduciary Financial Group LLC grew its position in shares of Sanofi (NASDAQ:SNY) by 3.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,775 shares of the company’s stock after purchasing an additional 253 shares during the period. Fiduciary Financial Group LLC’s holdings in Sanofi were worth $372,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. POM Investment Strategies LLC bought a new stake in Sanofi in the second quarter worth $25,000. Register Financial Advisors LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $29,000. Larson Financial Group LLC boosted its holdings in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares during the period. Palisade Asset Management LLC bought a new position in Sanofi during the 1st quarter worth approximately $31,000. Finally, Arrow Financial Corp purchased a new position in Sanofi in the 2nd quarter worth approximately $35,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.3 %

Shares of Sanofi stock opened at $54.96 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a market cap of $139.46 billion, a P/E ratio of 29.87, a PEG ratio of 1.57 and a beta of 0.60. The company’s fifty day simple moving average is $55.81 and its two-hundred day simple moving average is $51.34.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.95 earnings per share. Research analysts anticipate that Sanofi will post 4.25 EPS for the current year.

Analysts Set New Price Targets

SNY has been the topic of several analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.